




# Valproic acid (sodium valproate)

Statut de médicament essentiel 

Section: 5. Medicines for diseases of the nervous system > 5.1. Antiseizure medicines

EMLc

Codes ATC: N03AG01

Indication	Status epilepticus <span>Code ICD11: 8A66</span>
INN	Valproic acid
Type de médicament	Chemical agent
Type de liste	Liste complémentaire (EML) (EMLc)
Additional notes	Avoid use in pregnancy and in women and girls of child-bearing potential, unless alternative treatments are ineffective or not tolerated because of the high risk of birth defects and developmental disorders in children exposed to valproate in the womb.
Formulations	Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule ; 100 mg per mL in 10 mL ampoule ; 100 mg per mL in 3 mL ampoule
Historique des statuts LME	Ajouté pour la première fois en 2015 (TRS 994) Modifié en 2021 (TRS 1035) Modifié en 2023 (TRS 1049)
Sexe	Tous
Âge	Aussi recommandé pour les enfants
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets.</a> 
Wikipédia	<a href="#">Valproic acid (sodium valproate)</a> 
DrugBank	<a href="#">Valproic acid</a> 

## Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional vial size of valproic acid injection (100 mg/mL in 3 mL) on the EML and EMLc.

